Do self-management interventions in COPD patients work and which patients benefit most? An individual patient data meta-analysis by Jonkman, NH et al.
Do self-management interventions in COPD patients work and which
patients benefit most? An individual patient data meta-analysis.
Jonkman, NH; Westland, H; Trappenburg, JC; Groenwold, RH; Bischoff, EW; Bourbeau, J;
Bucknall, CE; Coultas, D; Effing, TW; Epton, MJ; Gallefoss, F; Garcia-Aymerich, J; Lloyd,
SM; Monninkhof, EM; Nguyen, HQ; van der Palen, J; Rice, KL; Sedeno, M; Taylor, SJ;
Troosters, T; Zwar, NA; Hoes, AW; Schuurmans, MJ
 
 
 
 
 
© 2016 Jonkman et al.
CC-BY-NC
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/15402
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
© 2016 Jonkman et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
International Journal of COPD 2016:11 2063–2074
International Journal of COPD Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2063
O r I g I n a l  r e s e a r C h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/COPD.S107884
Do self-management interventions in COPD 
patients work and which patients benefit most? 
an individual patient data meta-analysis
nini h Jonkman,1 heleen 
Westland,1 Jaap Ca Trappenburg,1 
rolf hh groenwold,2 erik WMa 
Bischoff,3 Jean Bourbeau,4 
Christine e Bucknall,5 David 
Coultas,6 Tanja W effing,7 Michael J 
epton,8 Frode gallefoss,9 Judith 
garcia-aymerich,10–12 suzanne M 
lloyd,13 evelyn M Monninkhof,2 
huong Q nguyen,14 Job van der 
Palen,15,16 Kathryn l rice,17 Maria 
sedeno,4 stephanie JC Taylor,18 
Thierry Troosters,19 nicholas a 
Zwar,20 arno W hoes,2 Marieke J 
schuurmans1
1Department of rehabilitation, nursing science 
and sports, 2Julius Center for health sciences and 
Primary Care, University Medical Center Utrecht, 
Utrecht, 3Department of Primary and Community 
Care, radboud University Medical Center, nijmegen, 
the netherlands; 4respiratory epidemiology and 
Clinical research Unit, Department of Medicine, 
Mcgill University health Center, Mcgill University, 
Montreal, QC, Canada; 5Department of respiratory 
Medicine, glasgow royal Infirmary, glasgow, UK; 
6Veterans administration Portland health Care 
system and Oregon health & science University, 
Portland, Or, Usa; 7Department of respiratory 
Medicine, repatriation general hospital, adelaide, 
sa, australia; 8Canterbury District health Board, 
respiratory services, Christchurch hospital, 
Christchurch, new Zealand; 9Department 
of Pulmonary Medicine, sorlandet hospital, 
Kristiansand, norway; 10Centre for research in 
environmental epidemiology Creal, 11Pompeu 
Fabra University, 12CIBer epidemiología y salud 
Pública CIBeresP, Barcelona, spain; 13robertson 
Centre for Biostatistics, University of glasgow, 
glasgow, UK; 14Department of research and 
evaluation, Kaiser Permanente southern California, 
Pasadena, Ca, Usa; 15Department of research 
Methodology, Measurement and Data analysis, 
University of Twente, 16Department of Clinical 
epidemiology, Medisch spectrum Twente, enschede, 
the netherlands; 17Division of Pulmonary, allergy, 
Critical Care and sleep Medicine, Minneapolis 
Veterans affairs health Care service and University 
of Minnesota, Minneapolis, Mn, Usa; 18Centre for 
Primary Care and Public health, Queen Mary 
University of london, london, UK; 19Department 
of rehabilitation sciences, Catholic University of 
leuven, leuven, Belgium; 20school of Public health 
and Community Medicine, UnsW australia, 
sydney, nsW, australia
Background: Self-management interventions are considered effective in patients with COPD, 
but trials have shown inconsistent results and it is unknown which patients benefit most. This 
study aimed to summarize the evidence on effectiveness of self-management interventions and 
identify subgroups of COPD patients who benefit most.
Methods: Randomized trials of self-management interventions between 1985 and 2013 were 
identified through a systematic literature search. Individual patient data of selected studies were 
requested from principal investigators and analyzed in an individual patient data meta-analysis 
using generalized mixed effects models.
Results: Fourteen trials representing 3,282 patients were included. Self-management inter-
ventions improved health-related quality of life at 12 months (standardized mean difference 
0.08, 95% confidence interval [CI] 0.00–0.16) and time to first respiratory-related hospitaliza-
tion (hazard ratio 0.79, 95% CI 0.66–0.94) and all-cause hospitalization (hazard ratio 0.80, 
95% CI 0.69–0.90), but had no effect on mortality. Prespecified subgroup analyses showed that 
interventions were more effective in males (6-month COPD-related hospitalization: interaction 
P=0.006), patients with severe lung function (6-month all-cause hospitalization: interaction 
P=0.016), moderate self-efficacy (12-month COPD-related hospitalization: interaction P=0.036), 
and high body mass index (6-month COPD-related hospitalization: interaction P=0.028 and 
6-month mortality: interaction P=0.026). In none of these subgroups, a consistent effect was 
shown on all relevant outcomes.
Conclusion: Self-management interventions exert positive effects in patients with COPD on 
respiratory-related and all-cause hospitalizations and modest effects on 12-month health-related 
quality of life, supporting the implementation of self-management strategies in clinical practice. 
Benefits seem similar across the subgroups studied and limiting self-management interventions 
to specific patient subgroups cannot be recommended.
Keywords: chronic obstructive pulmonary disease, individual patient data meta-analysis, 
self-management, subgroup analysis
Introduction
With over 60 million people affected, COPD is a major global health problem leading to 
substantial morbidity and mortality.1 In addition to the disease burden, COPD requires 
a major shift in patients’ daily life as they need to adhere to drug treatment, implement 
lifestyle changes, monitor signs and symptoms, and apply decision making on early 
treatment of exacerbations to prevent complications.2 Interventions to improve this 
self-management behavior in COPD patients have been receiving increasing attention 
and generally involve patient education and teaching skills to patients for monitoring 
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their condition, carrying out medical regimens, and chang-
ing their health behavior.3 A recent systematic review found 
positive effects on a range of outcomes, including health-
related quality of life (HRQoL), dyspnea, and health care 
utilization.4
Although the evidence favors self-management inter-
ventions, there seems to be a large heterogeneity in the 
effects of these interventions. Findings from five random-
ized trials, all based on the self-management program 
Living Well With COPD,5 were contradictory and have 
raised questions about large scale implementation of self-
management interventions in COPD patients. The first two 
trials reported large positive effects on respiratory-related 
hospitalization5 and the combined endpoint of respiratory-
related hospitalization and emergency department visit,6 but 
these promising findings could not be replicated in subse-
quent studies in the UK7 and the Netherlands.8 The fifth trial 
even reported higher mortality rates among patients in the 
self-management group and recruitment was terminated 
prematurely.9
Several researchers have postulated hypotheses in an 
attempt to explain the different outcomes of these five 
trials. The diversity among interventions, study populations, 
follow-up time, and outcome measures across these five trials 
compromise a generalization to real life. Patient factors might 
matter more than assumed to date and it has been suggested 
that adherence to and uptake of self-management interven-
tions are better in specific subgroups of patients.10 Currently, 
however, evidence on which subgroups are more likely to 
benefit from or respond negatively to self-management inter-
ventions is lacking. With this knowledge, clinicians might be 
able to target self-management interventions at those patients 
who benefit most.
Identification of such patient subgroups in individual 
trials is complicated, as these usually lack power. A meta-
analysis of individual patient data (IPD) enables a more 
reliable subgroup analysis with sufficient power due to the 
large numbers of patients included and by allowing a similar 
definition of subgroups across studies.11 Collecting the IPD 
from different trials also enables standardized statistical 
analyses and inclusion of data on available but unreported 
endpoints, which has additional advantages for analyzing the 
main effects of self-management interventions.
The present IPD meta-analysis aims to summarize the 
evidence on the effectiveness of COPD self-management 
interventions on relevant outcomes, including HRQoL, 
hospitalization, and mortality, with a particular focus on 
identifying subgroups of patients with COPD who are most 
likely to benefit from self-management interventions.
Methods
This IPD meta-analysis was conducted according to the 
guidelines in the Cochrane Handbook for Systematic Reviews 
of Interventions12 and followed a prespecified protocol.13
search and selection of studies
We searched the electronic databases PubMed, EMBASE, 
Cochrane Central Register of Controlled Trials, PsycINFO, 
and CINAHL from January 1985 through June 2013 and 
scrutinized the reference lists of identified relevant system-
atic reviews.
With no general agreement on an operational definition 
of self-management interventions, an international group of 
self-management research experts set out to reach consensus 
on the criteria for defining self-management intervention. 
There is general agreement on the multifaceted nature of self-
management interventions.3,4,14 Therefore, self-management 
interventions were defined as interventions providing 
information to patients and including minimally two of the 
following components: 1) stimulation of sign/symptom 
monitoring, 2) education in problem solving skills (ie, stress/
symptom management), enhancement of 3) medical treat-
ment adherence, 4) physical activity, 5) smoking cessation, 
or 6) dietary intake. The emphasis for each component had to 
be on enhancing the patient’s active role and responsibility. 
Therefore, interventions focusing on pulmonary rehabilita-
tion were not considered eligible for this meta-analysis.
Studies were selected by two researchers working inde-
pendently (NHJ and HW) and included if they 1) met the 
requirements of the definition of self-management interven-
tion above, 2) had a randomized trial design with concealed 
allocation to treatment, 3) included patients with an estab-
lished diagnosis of COPD, 4) compared the self-management 
intervention to usual care or another self-management 
intervention, 5) reported data on one or more of the selected 
outcomes, 6) followed patients for at least 6 months, and 
7) were reported in English, Dutch, French, German, Italian, 
Portuguese, or Spanish.
Methodological quality was assessed by two researchers 
independently (NHJ and HW) using three relevant criteria 
from the “Risk of bias” tool from the Cochrane Collaboration:12 
1) random concealed allocation to treatment, 2) intention-
to-treat analysis, and 3) absence of other major sources of 
bias (eg, high drop-out rates, risk of contamination). Any 
discrepancies were solved through consensus with a third 
researcher (JCAT). Studies that scored a high risk of bias 
on one or more criteria were defined as “high risk of bias”. 
Those studies were included, but their impact on the results 
was assessed in a sensitivity analysis.
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Data collection
The principal investigators of selected studies were invited 
to participate in this IPD meta-analysis and share their 
de-identified trial data. Data from each trial were checked on 
range, extreme values, internal consistency, missing values, 
and consistency with published reports. Questions that arose 
during the data checking were discussed and resolved with 
principal investigators. Details on requested variables, data 
management, project management, and ethical considerations 
can be found in the published protocol.13
Outcomes
The main outcomes of this study included: HRQoL at 
6 and 12 months (as measured with Chronic Respiratory 
Questionnaire15 or St George Respiratory Questionnaire16), 
respiratory-related hospitalization (time-to-first-event, within 
6 and 12 months), all-cause hospitalizations (time-to-first-
event, within 6 and 12 months), and mortality (time-to-event, 
within 6 and 12 months). Additional outcomes analyzed were 
generic quality of life (QoL), as measured with the Short Form 
Health Survey,17 and total days of respiratory-related and all-
cause hospital stay since enrollment at 6 and 12 months.
Patient-specific effect modifiers
Clinically relevant potential effect modifiers (ie, variables, 
such as sex or age) were prespecified based on the self-
management literature and availability of data across trials 
and presented in Table 1 (along with the baseline data). 
Based on teleconferences with the principal investigators, we 
decided to collect data on baseline exacerbation frequency, 
in addition to the potential effect modifiers prespecified in 
the protocol.13
Table 1 Baseline characteristics of COPD patients
Determinant Categories Control (n=1,492) Intervention (n=1,790) Total (N=3,282)
sex Male
Female
999 (67.0)
492 (33.0)
1,151 (64.3)
639 (35.7)
2,150 (65.5)
1,131 (34.5)
age Mean (sD) years
,65 years
65–75 years
.75 years
68.3 (9.6)
487 (32.8)
627 (42.2)
371 (25.0)
67.9 (9.6)
619 (34.7)
780 (43.7)
387 (21.7)
68.1 (9.6)
1,106 (33.8)
1,407 (43.0)
758 (23.2)
Airflow obstruction Mean (sD) FeV1 in % predicted
$50% FeV1 in % of predicted
,50% FeV1 in % of predicted
47.3 (18.8)
617 (42.1)
847 (57.9)
48.0 (18.9)
772 (43.5)
1,001 (56.5)
47.7 (18.9)
1,389 (42.9)
1,848 (57.1)
Dyspneaa low level of breathlessness
high level of breathlessness
151 (37.4)
253 (62.6)
275 (50.2)
273 (49.8)
426 (44.7)
526 (55.3)
Comorbidity indexb no comorbid conditions
Comorbid conditions in one cluster
Comorbid conditions in $2 clusters 
366 (32.4)
291 (25.8)
471 (41.8)
428 (32.9)
326 (25.0)
548 (42.1)
794 (32.7)
617 (25.4)
1,019 (41.9)
Depressionc no/mild depression
Moderate/severe depression
414 (70.9)
170 (29.1)
546 (74.0)
192 (26.0)
960 (72.6)
362 (27.4)
level of education Primary education or below
secondary education
higher education
313 (39.6)
351 (44.4)
127 (16.1)
391 (38.3)
456 (44.7)
173 (17.0)
704 (38.9)
807 (44.6)
300 (16.6)
Self-efficacyd Low self-efficacy
Moderate self-efficacy
High self-efficacy 
185 (31.7)
216 (37.0)
183 (31.3)
290 (33.9)
268 (31.3)
297 (34.7)
475 (33.0)
484 (33.6)
480 (33.4)
living status living with others
living alone
548 (71.2)
222 (28.8)
572 (68.1)
268 (31.9)
1,120 (69.6)
490 (30.4)
Body mass index Mean (sD)
,25
25–29.99
$30 
27.2 (6.5)
539 (40.1)
429 (31.9)
376 (28.0)
27.1 (6.2)
641 (39.4)
568 (34.9)
418 (25.7)
27.1 (6.3)
1,180 (39.7)
997 (33.6)
794 (26.7)
smoking status Current nonsmoker
Current smoker
1,036 (71.8)
407 (28.2)
1,225 (71.1)
499 (28.9)
2,261 (71.4)
906 (28.6)
exacerbation frequency 0 exacerbations
1 exacerbation
$2 exacerbations 
188 (31.1)
134 (22.2)
282 (46.7)
194 (30.8)
122 (19.4)
314 (49.8)
382 (31.0)
256 (20.7)
596 (48.3)
Notes: Values are expressed as mean (sD) or n (%). aBased on score modified Medical Research Council dyspnea scale47 and categorized mMrC $3 or mMrC $2 as high 
level of breathlessness. bBased on clusters Cumulative Illness rating scale.48 cBased on validated cutoff scores of instrument used in each specific study. dCategories based on 
tertile scores computed within each specific study.
Abbreviations: FeV1, forced expiratory volume in 1 second; sD, standard deviation.
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statistical analysis
The principal investigators of the individual trials were 
involved in the process of designing a detailed plan for 
statistical analysis and agreed upon this prior to data analysis. 
Missing values were imputed within studies only using 
multiple imputation by chained equations (overall 2.7% 
missing data, except 33.7% for HRQoL follow-up data).18 
For each study, 25 multiple imputed datasets were created 
and used for the primary analyses. Within these analyses, 
a one-stage approach was used, that is, simultaneously 
analyzing all observations while accounting for clustering 
of observations within studies.19 Results of imputed datasets 
were pooled using Rubin’s rules.20
All analyses were carried out according to the intention-
to-treat principle. For time-to-event endpoints, effects of 
self-management were quantified by estimating hazard ratios 
using Cox proportional hazard models, including a frailty 
term to account for clustering within studies. The continu-
ous outcomes (HRQoL and generic oL) were quantified by 
standardized mean differences (SMD) between intervention 
arms and analyzed using linear mixed effects models. Using 
the SMD, results are converted to a uniform scale represent-
ing the intervention effect relative to the observed variability 
in one study before pooling the results of different studies. 
Binary outcome data (mortality, respiratory-related, and 
all-cause hospitalization) were analyzed with log-binomial 
mixed effects models, which estimated risk ratios (RRs) or 
odds ratios (ORs) in case of nonconvergence of a model, 
respectively. To correctly model the presence of overdisper-
sion in the count data of total days of hospital stay, negative 
binomial mixed effects models were used to estimate relative 
length of stay. All mixed effects models included a random 
intercept and a random slope for the treatment effect to take 
clustering at study level into account.
To assess whether the effect of self-management was 
modified by patient characteristics, the aforementioned 
models were extended with interaction terms for the patient 
characteristics included in Table 1. The independent variables 
in the models were random intercept, random slope, alloca-
tion to self-management, patient characteristic, and interac-
tion term (treatment allocation*patient characteristic). This 
was performed for each patient characteristic separately. All 
effect modifiers with P,0.10 for the interaction (likelihood 
ratio test) in the univariable analysis were included in a mul-
tivariable model to estimate the effect of self-management 
within subgroups independent of other potential effect modi-
fiers. Effect modification was considered significant if the 
interaction term showed P,0.05 in the final model.
As a sensitivity analysis, we investigated the potential of 
retrieval bias (ie, bias due to selective inclusion of studies in 
the IPD meta-analysis) by pooling the published main effects 
of studies for which IPD were unavailable with the main 
effects of included studies in a random effects meta-analysis. 
To assess the impact of studies of lower methodological 
quality on the main effects, an additional sensitivity analysis 
was performed, including only studies with a low risk of 
bias. Three additional sensitivity analyses were performed 
to assess the robustness of findings from the subgroup 
analyses: 1) a complete case analysis was carried out to 
assess the effect of imputing data, and analyses were repeated 
by 2) excluding older studies (recruitment before 2001) and 
3) excluding the largest trial.6 All analyses were performed 
in R for Windows version 3.1.1 (R Development Core 
Team. Released 2013. Vienna, Austria: R Foundation for 
Statistical Computing).
Results
Twenty-one studies met the inclusion criteria. Seven studies 
were not included in this IPD meta-analysis.9,21–26 We could 
not contact the investigators of three studies;21,23,24 for two 
studies, the investigators could not obtain approval from 
their local Institutional Review Board;9,22 the data from 
one study were no longer available;25 and investigators of 
one study could not participate due to time constraints.26 
The investigators of the other 14 studies participated in 
this IPD meta-analysis, resulting in the inclusion of data on 
3,282 patients.
Patient characteristics are presented in Table 1. Not all 
studies measured the same baseline characteristics; only 
sex, age, and forced expiratory volume in 1 second in % of 
predicted were assessed in all studies. The majority of included 
patients were male (65.5%). Patients had a mean age of 
68.1 years (±9.6) and a mean forced expiratory volume in 
1 second in % of predicted of 47.7% (±18.9%). The majority 
of patients had high breathlessness scores (55.3%). Apart 
from dyspnea classification, all baseline variables were well 
balanced between control and intervention groups.
Table 2 presents the characteristics of included studies.5–8,27–36 
Seven studies recruited participants in a clinic or hospital 
setting,5–7,27,29,30,32 five studies in general practice,8,28,31,34,36 and 
two in both settings.33,35 The sample size of studies ranged 
from 5330 to 743 patients.6 Self-management interventions 
varied across studies: a majority included an action plan 
and consisted of individual sessions with a nurse, and some 
involved group contacts. Duration of interventions ranged 
from 1 day31 to 24 months.8
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Main effects of self-management 
interventions
Self-management interventions improved HRQoL at 
12 months (SMD 0.08, 95% confidence interval [CI] 
0.00–0.16), but not at 6 months (SMD 0.05, 95% CI −0.05 
to 0.15) (Table 3). The interventions improved time to first 
respiratory-related hospitalization (hazard ratio 0.79, 95% CI 
0.66–0.94). Although there was no clear effect on respiratory-
related hospitalization within 6 months, there was a significant 
risk reduction at 12 months (RR 0.77, 95% CI 0.64–0.93). 
Self-management interventions improved the time to first all-
cause hospitalization (hazard ratio 0.80, 95% CI 0.69–0.90) 
and risk of hospitalization within 6 months (RR 0.81, 95% 
CI 0.67–0.97) and 12 months (RR 0.84, 95% CI 0.73–0.96). 
There was no effect of self-management on mortality. Figure 1 
shows the effects across studies for HRQoL, respiratory-
related and all-cause hospitalization, and mortality. Sensitiv-
ity analyses of including the published effects of studies for 
which no IPD were available resulted in similar effects of the 
self-management interventions (Supplementary material). No 
effects were observed on the additional outcomes of generic 
QoL or total days in hospital (Supplementary material).
effects in subgroups of patients
The final models in the prespecified subgroup analysis 
revealed no consistent effect modification by any patient 
characteristic across all relevant outcomes (Table 4), but 
the effect on specific outcomes differed according to some 
of the patient characteristics we studied. A positive effect 
of self-management interventions was observed in males 
(OR 0.61, 95% CI 0.41–0.90) compared to females on the 
outcome respiratory-related hospitalization within 6 months 
(OR 1.24, 95% CI 0.76–2.02; interaction P=0.006). Patients 
with severe airflow limitation showed a reduced risk on all-
cause hospitalization within 6 months when allocated to the 
intervention (RR 0.71, 95% CI 0.58–0.88), while there was 
no treatment effect in patients with $50% forced expira-
tory volume in 1 second in % of predicted (RR 1.02, 95% 
CI 0.78–1.34; interaction P=0.016). Obese patients showed 
the most protective effects of self-management interventions 
on respiratory-related hospitalization within 6 months (OR 
0.44, 95% CI 0.27–0.72; interaction P=0.038) and mortal-
ity within 6 months (OR 0.35, 95% CI 0.11–1.10; interac-
tion P=0.026). Finally, patients with baseline moderate 
self-efficacy scores showed the largest reduction in risk 
on respiratory-related hospitalization within 12 months 
(OR 0.39, 95% CI 0.21–0.75) compared to patients with 
low (OR 0.85, 95% CI 0.46–1.59) or high levels of self-
efficacy (OR 0.89, 95% CI 0.47–1.71; interaction P=0.036). 
Additional analyses for generic QoL and total days in hospital 
did not reveal different insights (Supplementary material). 
Subgroup analysis according to exacerbation frequency was 
impossible due to too diverse data collection at baseline and 
comparison of subgroups in individual trials did not reveal 
consistent effects across studies (Supplementary material). 
Sensitivity analyses to assess the robustness of the subgroup 
effects yielded similar findings to the primary analysis.
Discussion
This IPD meta-analysis of 14 randomized trials showed 
that self-management interventions exerted positive effects 
in COPD patients on respiratory-related and all-cause 
Table 3 effects of self-management interventions in patients with COPD
Outcome N studies n patients Effect measure Treatment effect 95% CI
health-related quality of life
at 6 months 9 1,876 sMD 0.05 (−0.05–0.15)
at 12 months 10 2,663 sMD 0.08 (0.00–0.16)
respiratory-related hospitalization
Time-to-first-event 6 1,872 hr 0.79 (0.66–0.94)
Within 6 months 8 2,347 rr 0.87 (0.69–1.09)
Within 12 months 9 2,426 rr 0.77 (0.64–0.93)
all-cause hospitalization
Time-to-first-event 4 1,559 hr 0.80 (0.69–0.93)
Within 6 months 6 2,034 rr 0.81 (0.67–0.97)
Within 12 months 5 1,817 rr 0.84 (0.73–0.96)
Mortality
Time-to-event 7 2,120 hr 1.02 (0.76–1.37)
Within 6 months 9 2,490 rr 1.06 (0.62–1.82)
Within 12 months 7 2,182 rr 1.04 (0.64–1.69)
Abbreviations: CI, confidence interval; HR, hazard ratio; RR, risk ratio; SMD, standardized mean difference.
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hospitalization. Self-management interventions also resulted 
in small improvements on HRQoL at 12 months, but had no 
effect on HRQoL at 6 months or on mortality. One novel 
aspect from this study was the prespecified subgroup analy-
ses, which did not show a consistent pattern across health 
outcomes of subgroups of patients benefiting most from the 
self-management interventions.
The main effects reported by the present study are in line 
with a recent Cochrane review on self-management trials in 
COPD patients.4 Like the present study, the authors did not 
find an effect of self-management on mortality. However, 
the follow-up period of 12 months may have been too short 
to elicit an effect on this outcome. Although the Cochrane 
review applied a wider definition of “self-management 
interventions” and could include all eligible trials (N=23 vs 
N=14 in this IPD meta-analysis, respectively), we were able 
to include more recently conducted studies (N=6) of which 
some have cast doubts on the usefulness of self-management 
in COPD patients.7,8 By including data from these recent 
studies as well as performing a sensitivity analysis, includ-
ing the published results of the prematurely terminated 
trial,9 the present study provides more extensive evidence 
that self-management interventions elicit positive effects in 
COPD patients and can be considered safe. However, the 
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Figure 1 Forest plot of effects of self-management interventions on health-related quality of life, respiratory-related and all-cause hospitalization, and mortality in patients 
with COPD.
Abbreviations: CI, confidence interval; HR, hazard ratio, SMD, standardized mean difference.
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Table 4 effects of self-management interventions in subgroups of patients with COPD
Outcome n 
patients
Subgroup Effect 
measure
Univariable analysis Multivariable analysis
Treatment 
effect
95% CI P-value for 
interaction
Treatment 
effect
95% CI P-value for 
interaction
health-related quality of life
at 6 months no subgroup effects
at 12 months no subgroup effects
respiratory-related hospitalization
Time-to-first-event 1,214 Males hr 0.68 (0.54–0.84) 0.022 0.78 (0.55–1.09) 0.130
497 Females 1.05 (0.78–1.42) 1.07 (0.78–1.48)
549 no comorbidities hr 0.93 (0.72–1.20) 0.073 0.78 (0.55–1.09) 0.206
380 Comorbidities  
in one cluster
0.52 (0.33–0.80) 0.48 (0.31–0.76)
710 Comorbidities  
in .1 cluster
0.72 (0.52–1.00) 0.70 (0.50–0.97)
6 months 1,544 Males Or 0.67 (0.50–0.88) 0.005 0.61 (0.41–0.90) 0.006
803 Females 1.36 (0.91–2.04) 1.24 (0.76–2.02)
835 BMI ,25 Or 0.77 (0.54–1.11) 0.043 0.61 (0.41–0.90) 0.038
636 BMI 25–29.99 1.23 (0.78–1.93) 1.01 (0.63–1.61)
618 BMI $30 0.55 (0.34–0.88) 0.44 (0.27–0.72)
12 months 281 Low self-efficacy Or 0.85 (0.46–1.59) 0.036 a
 277 Moderate  
self-efficacy
0.39 (0.21–0.75)
 250 High self-efficacy 0.89 (0.47–1.71)
all-cause hospitalization
Time-to-first-event 539 no comorbidities hr 0.88 (0.71–1.09) 0.056 a
384 Comorbidities in 
one cluster
0.57 (0.41–0.78)
636 Comorbidities  
in .1 cluster
0.89 (0.68–1.15)
6 months 698 $50% FeV1  
% predicted
rr 1.02 (0.78–1.34) 0.016 a
1,336 ,50% FeV1  
% predicted
0.71 (0.58–0.88)
12 months 614 $50% FeV1  
% predicted 
Or 1.03 (0.73–1.46) 0.032 1.30 (0.54–3.12) 0.232
 1,203 ,50% FeV1  
% predicted
0.63 (0.49–0.81) 0.82 (0.40–1.68)
222 Low self-efficacy Or 0.93 (0.47–1.86) 0.047 1.30 (0.54–3.12) 0.062
239 Moderate  
self-efficacy
0.35 (0.18–0.71) 0.52 (0.21–1.29)
195 High self-efficacy 0.92 (0.46–1.86) 1.31 (0.54–3.20)
Mortality
Time-to-event 549 no comorbidities hr 1.56 (0.90–2.72) 0.075 b
380 Comorbidities  
in one cluster
0.66 (0.29–1.49)
710 Comorbidities  
in .1 cluster
0.77 (0.46–1.31)
140 less 
breathlessness 
hr 5.33 (0.69–40.91) 0.091 b
248 More 
breathlessness
0.83 (0.22–3.09)
6 months 1,707 Males Or 0.79 (0.42–1.49) 0.071 1.40 (0.64–3.05) 0.123
 783 Females 1.83 (0.82–4.11) 2.89 (1.19–7.02)
 976 BMI ,25 Or 1.83 (0.94–3.55) 0.016 1.40 (0.64–3.05) 0.026
 817 BMI 25–29.99 0.70 (0.33–1.51) 0.54 (0.23–1.26)
 697 BMI $30 0.46 (0.15–1.35) 0.35 (0.11–1.10)
12 months 1,557 Males rr 0.85 (0.51–1.42) 0.092 1.18 (0.62–2.26) 0.445
625 Females 1.59 (0.77–3.28) 1.57 (0.80–3.08)
(Continued)
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positive effects observed for HRQoL at 12 months should 
be considered modest improvements, and no effects were 
observed at 6 months. It also remains questionable whether 
the statistical difference that we observed is a clinically 
important difference for COPD patients. Furthermore, it 
remains questionable whether our findings also apply to 
COPD patients recently discharged from hospital. A recently 
published systematic review on self-management interven-
tions in this group of patients found that positive effects were 
limited to HRQoL,37 but the authors applied rather wide inclu-
sion criteria for the interventions, resulting in the inclusion 
of many interventions with only a limited self-management 
component compared to the present study.
The novel aspect of the present study compared to the 
previously conducted systematic reviews was the prespeci-
fied subgroup analysis. This subgroup analysis revealed 
larger effects of self-management interventions in males, 
patients with more severe airflow limitation, patients with 
moderate levels of self-efficacy, and obese patients, but 
only on some outcomes. To date, differential effects of self-
management interventions in subgroups of COPD patients 
have scarcely been examined. One study included in this 
IPD meta-analysis analyzed response of subgroups of COPD 
patients to the self-management intervention on hospitaliza-
tion or death.7 The preplanned subgroup analyses did not 
show any evidence of differential effects, but the authors 
found that only 42% of intervention group subjects learnt 
to self-manage successfully. The successful self-managing 
patients had significantly reduced hospitalization rate.7 The 
present IPD meta-analysis, with more power to perform sub-
group analyses, suggested larger effects of self-management 
interventions on respiratory-related hospitalization as well 
as mortality at 6 months in obese patients. Although effect 
modification by body mass index has not yet been analyzed 
in COPD patients in the context of self-management interven-
tions, evidence is starting to emerge that overweight or obese 
patients encompass a specific phenotype of COPD patients.38 
It is possible that this particular phenotype of COPD patients 
responds differently to self-management interventions. Our 
analyses only revealed differential effects of obesity on the 
outcomes respiratory-related hospitalization at 6 months 
and mortality at 6 months. Effects at 12 months were in a 
similar direction, but these were not statistically significant. 
Previous efforts to assess the influence of body mass index on 
effectiveness of pulmonary rehabilitation have also yielded 
inconsistent results.39,40 Although our subgroup analysis was 
prespecified13 and yielded several statistically significant 
findings, the high number of analyses increases the chance 
of false-positive findings. With no consistent pattern across 
multiple health outcomes, the subgroup results should be 
interpreted with caution.41 Limiting self-management sup-
port to specific patient subgroups cannot be recommended at 
this stage and further research is therefore needed to confirm 
the observed subgroup effects for other health outcomes. 
Reassuringly, there were no indications in our analyses that 
certain subgroups of patients responded in a negative way 
to the self-management interventions.
To our knowledge, the present study is the first to pool 
and reanalyze the original data of a large number of random-
ized trials on self-management interventions in patients with 
COPD and transcends the previously conducted systematic 
reviews.4,37 An IPD meta-analysis is a resource intensive 
approach, given the time and efforts needed for collecting 
and merging the raw patient data.42 As a result, no articles 
published after June 2013 were included for analysis. The 
high response rate of principal investigators (66.7%), large 
number of patients included (n=3,282), prespecified statistical 
plan, and close collaboration with the principal investigators 
through regular teleconferences contribute to the robustness 
of our findings. There are several methodological limitations 
worth considering. First, in spite of numerous efforts to con-
tact and convince the principal investigators of all eligible 
Table 4 (Continued)
Outcome n 
patients
Subgroup Effect 
measure
Univariable analysis Multivariable analysis
Treatment 
effect
95% CI P-value for 
interaction
Treatment 
effect
95% CI P-value for 
interaction
627 no Comorbidities rr 1.37 (0.80–2.35) 0.074 1.18 (0.62–2.26) 0.213
485 Comorbidities  
in 1 cluster
0.64 (0.31–1.30) 0.60 (0.30–1.25)
669 Comorbidities  
in .1 cluster
0.71 (0.43–1.16) 0.70 (0.43–1.15)
Notes: Results of the subgroup analyses are only presented if a potential effect modifier showed an effect with P,0.10 in the univariable analysis. aMultivariable analysis was 
only performed if $2 potential effect modifiers in the univariable analysis to adjust for other potential effect modifiers. bMultivariable analysis not executed as this would 
result in n=1 study.
Abbreviations: BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; hr, hazard 
ratio; Or, odds ratio; rr, risk ratio.
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studies, we could not obtain the data of seven randomized 
trials, including the prematurely aborted trial.9 However, the 
sensitivity analysis of pooling the published results of those 
trials with the main effects of included studies showed that 
this did not alter our findings (Supplementary material).
Second, we assumed all interventions to be homogeneous 
self-management interventions in our analyses, but the 
included self-management intervention designs differed from 
each other in terms of dose, mode, and content. Without con-
sistent evidence for subgroups of patients benefiting across 
various health outcomes, we could hypothesize that specific 
subgroups of patients only respond better to particular com-
ponents of interventions (ie, action plans in self-management 
interventions). Future research addressing various interven-
tions is needed to identify what type of intervention works for 
whom. Nevertheless, the reported main effects on HRQoL at 
12 months, and respiratory-related and all-cause hospitaliza-
tion were consistent across cultures and health care settings. 
This indicates that, despite their diversity, self-management 
interventions exert positive effects, even in different formats 
and differing patient populations.
Third, this IPD meta-analysis was highly dependent 
on data that were previously collected. This seriously lim-
ited our choice of potential effect modifiers. Exacerbation 
frequency has attracted considerable attention in recent 
years,43 but due to the diverse data collection across stud-
ies, the quality of available data on baseline exacerbation 
rate was too low to enable a pooled analysis of this patient 
characteristic. This emphasizes the urgent need for a uniform 
operational definition of exacerbations within the field of 
COPD research.44 For similar reasons, we could not study 
other potentially relevant variables, such as Global initiative 
for chronic Obstructive Lung Disease stage, coping style, 
disease perception, and adherence. Previous studies have 
shown that even though adherence to self-management 
treatment is a challenge for a majority of patients enrolled 
in randomized trials, the patients who actually applied those 
new self-management skills showed better outcomes.7,45 
This suggests that emphasis should be placed on patients’ 
ability to apply self-management guidelines and subse-
quently change their behavior as this is a prerequisite for 
better outcomes. Collection of data on intervention delivery, 
treatment adherence, and behavior change in randomized 
trials, particularly on complex interventions, such as self-
management, is indispensable to identify patients most likely 
to adhere to the self-management interventions and in whom 
these interventions may improve prognosis.46
Conclusion
Self-management interventions exert positive effects in 
patients with COPD on respiratory-related and all-cause 
hospitalization and modest improvement of HRQoL at 
12 months, but do not show an effect on mortality. These 
benefits seem similar across the subgroups of patients 
studied as subgroup analysis did not reveal a consistent pat-
tern across different health outcomes. Our findings support 
implementation of self-management strategies in practice, 
but targeting self-management interventions at specific 
subgroups of patients cannot be recommended based on the 
current evidence.
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